OncoStemyx uses approved drugs not normally used for cancer treatment to create a novel synergistic interaction that targets cancer stem cells and overcomes chemoresistance.
We have a novel drug combination of approved drugs that can target chemoresistance in several cancer types by inducing stochastic cell death leading to a robust priming of an enhanced T-cell killing response.
The preclinical phase complete, we will be conducting a Phase 1B clinical trial using our drug in 2019. We anticipate receiving FDA approval in 2-3 years.